Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
New Therapeutic Targets and Pathological Mechanisms for Treatment of Pulmonary...
share announcement

New Therapeutic Targets and Pathological Mechanisms for Treatment of Pulmonary Hypertension

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 9087

Special Issue Editors

Dr. Jin-Song Bian

E-Mail Website
Guest Editor
Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China
Interests: biology of Na+/K+ ATPase; biological functions of hydrogen sulfide; pulmonary hypertension; cardioprotection; neurodegenerative diseases
Dr. Lin Deng

E-Mail Website
Guest Editor
Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China
Interests: pulmonary hypertension; cardiovascular disease; noncoding RNA; prostate cancer

Special Issue Information

Dear Colleagues,

Pulmonary arterial hypertension (PAH) is a fatal disease characterized by remodeling of the distal pulmonary arteries and increased pulmonary vascular resistance, leading to right ventricular failure and eventually death. Existing therapies act mainly as vasodilators but cannot reverse the disease progress and significantly improve survival. Endothelial cell integrity loss and endothelial dysfunction result in the exposure of underlying cells to the circulating factors, which promote smooth muscle cell and adventitial fibroblasts proliferation and resistance to apoptosis, inducing DNA damage, infiltration of inflammatory and immune cells, and endothelial-to-mesenchymal transition (EndMT), leading to the muscularization of pulmonary vessels. The dysregulation of TGF-β and BMP signaling, noncoding RNAs, and exosomal RNAs also contributes to the pathogenesis of vascular remodeling in PAH disease. This Special Issue focuses on novel therapeutic targets in pulmonary vascular remodeling and right heart failure. We warmly welcome submissions, including original papers and reviews, on this widely discussed topic.

Dr. Jin-Song Bian
Dr. Lin Deng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary arterial hypertension
  • vascular remodeling
  • TGF-β/BMP signaling
  • endothelial dysfunctions
  • endothelial-to-mesenchymal transition
  • non-coding RNAs
  • exosomes
  • right ventricle hypertrophy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

24 pages, 7794 KiB  
Article
Andrographolide Attenuates Established Pulmonary Hypertension via Rescue of Vascular Remodeling
by Xiaowei Nie, Chenyou Shen, Jianxin Tan, Xusheng Yang, Wei Wang, Youai Dai, Haijian Sun, Zhiyuan Wu and Jingyu Chen
Biomolecules 2021, 11(12), 1801; https://doi.org/10.3390/biom11121801 - 30 Nov 2021
Cited by 6 | Viewed by 2875
Abstract
Pulmonary hypertension (PH) is characterized by vascular remodeling caused by marked proliferation of pulmonary artery smooth muscle cells (PASMCs). Andrographolide (ANDRO) is a potent anti-inflammatory agent which possesses antioxidant, and has anticarcinogenic activity. The present study examined potential therapeutic effects of ANDRO on [...] Read more.
Pulmonary hypertension (PH) is characterized by vascular remodeling caused by marked proliferation of pulmonary artery smooth muscle cells (PASMCs). Andrographolide (ANDRO) is a potent anti-inflammatory agent which possesses antioxidant, and has anticarcinogenic activity. The present study examined potential therapeutic effects of ANDRO on PH in both chronic hypoxia and Sugen5416/hypoxia mouse PH models. Effects of ANDRO were also studied in cultured human PASMCs isolated from either healthy donors or PH patients. In vivo, ANDRO decreased distal pulmonary arteries (PAs) remodeling, mean PA pressure and right ventricular hypertrophy in chronic hypoxia- and Sugen/hypoxia-induced PH in mice. ANDRO reduced cell viability, proliferation and migration, but increased cell apoptosis in the PASMCs isolated from PH patients. ANDRO also reversed the dysfunctional bone morphogenetic protein receptor type-2 (BMPR2) signaling, suppressed [Ca2+]i elevation, reactive oxygen species (ROS) generation, and the upregulated expression of IL-6 and IL-8, ET-1 and VEGF in PASMCs from PH patients. Moreover, ANDRO significantly attenuated the activation of TLR4/NF-κB, ERK- and JNK-MAPK signaling pathways and reversed the inhibition of p38-MAPK in PASMCs of PH patients. Further, ANDRO blocked hypoxia-triggered ROS generation by suppressing NADPH oxidase (NOX) activation and augmenting nuclear factor erythroid 2-related factor 2 (Nrf2) expression both in vitro and in vivo. Conventional pulmonary vasodilators have limited efficacy for the treatment of severe PH. We demonstrated that ANDRO may reverse pulmonary vascular remodeling through modulation of NOX/Nrf2-mediated oxidative stress and NF-κB-mediated inflammation. Our findings suggest that ANDRO may have therapeutic value in the treatment of PH. Full article
(This article belongs to the Special Issue New Therapeutic Targets and Pathological Mechanisms for Treatment of Pulmonary Hypertension)
►▼ Show Figures

Figure 1

Review

Jump to: Research

28 pages, 1161 KiB  
Review
The Landscape of Noncoding RNA in Pulmonary Hypertension
by Lin Deng, Xiaofeng Han, Ziping Wang, Xiaowei Nie and Jinsong Bian
Biomolecules 2022, 12(6), 796; https://doi.org/10.3390/biom12060796 - 07 Jun 2022
Cited by 8 | Viewed by 3732
Abstract
The transcriptome of pulmonary hypertension (PH) is complex and highly genetically heterogeneous, with noncoding RNA transcripts playing crucial roles. The majority of RNAs in the noncoding transcriptome are long noncoding RNAs (lncRNAs) with less circular RNAs (circRNAs), which are two characteristics gaining increasing [...] Read more.
The transcriptome of pulmonary hypertension (PH) is complex and highly genetically heterogeneous, with noncoding RNA transcripts playing crucial roles. The majority of RNAs in the noncoding transcriptome are long noncoding RNAs (lncRNAs) with less circular RNAs (circRNAs), which are two characteristics gaining increasing attention in the forefront of RNA research field. These noncoding transcripts (especially lncRNAs and circRNAs) exert important regulatory functions in PH and emerge as potential disease biomarkers and therapeutic targets. Recent technological advancements have established great momentum for discovery and functional characterization of ncRNAs, which include broad transcriptome sequencing such as bulk RNA-sequence, single-cell and spatial transcriptomics, and RNA-protein/RNA interactions. In this review, we summarize the current research on the classification, biogenesis, and the biological functions and molecular mechanisms of these noncoding RNAs (ncRNAs) involved in the pulmonary vascular remodeling in PH. Furthermore, we highlight the utility and challenges of using these ncRNAs as biomarkers and therapeutics in PH. Full article
(This article belongs to the Special Issue New Therapeutic Targets and Pathological Mechanisms for Treatment of Pulmonary Hypertension)
►▼ Show Figures

Figure 1

8 pages, 968 KiB  
Review
Implications of Hydrogen Sulfide in Development of Pulmonary Hypertension
by Yan Sun, Chaoshu Tang, Hongfang Jin and Junbao Du
Biomolecules 2022, 12(6), 772; https://doi.org/10.3390/biom12060772 - 01 Jun 2022
Cited by 6 | Viewed by 1893
Abstract
The pathological mechanisms underlying pulmonary hypertension (PH), as well as its treatment strategy, are crucial issues in this field. This review aimed to summarize the pathological mechanisms by which the hydrogen sulfide (H2S) pathway contributes to PH development and its future [...] Read more.
The pathological mechanisms underlying pulmonary hypertension (PH), as well as its treatment strategy, are crucial issues in this field. This review aimed to summarize the pathological mechanisms by which the hydrogen sulfide (H2S) pathway contributes to PH development and its future implications. The data in this review were obtained from Medline and PubMed sources up to 2022 using the search terms "hydrogen sulfide" and "pulmonary hypertension". In the review, we discussed the significance of endogenous H2S pathway alteration in PH development and showed the advance of the role of H2S as the third gasotransmitter in the mechanisms for hypoxic PH, monocrotaline-induced PH, high blood flow-induced PH, and congenital heart disease-associated PH. Notably, H2S plays a crucial role in the development of PH via certain mechanisms, such as inhibiting the proliferation of pulmonary artery smooth muscle cells, suppressing the inflammation and oxidative stress of pulmonary artery endothelial cells, inducing pulmonary artery smooth muscle cell apoptosis, and interacting with other gaseous signaling pathways. Recently, a variety of H2S donors were developed, including naturally occurring donors and synthetic H2S donors. Therefore, understanding the role of H2S in PH development may help in further exploring novel potential therapeutic targets of PH. Full article
(This article belongs to the Special Issue New Therapeutic Targets and Pathological Mechanisms for Treatment of Pulmonary Hypertension)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop